Clinical Trial

Study of ESG406 in Adults With Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is an open-label, dose-escalation and cohort expansion Phase I study, aiming to evaluate the safety, tolerability, PK characteristics and preliminary efficacy of ESG406, and determine the MTD, RP2D and administration regimens of ESG406. The study includes the dose escalation study in Phase Ia and the cohort expansion study in Phase Ib.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-13.
Status change: Not Yet Recruiting → Recruiting 2025-09-08
Trial Details
NCT Number NCT06979674
Lead Sponsor Shanghai Escugen Biotechnology Co., Ltd
Conditions Locally Advanced/Metastatic Solid Tumors
Enrollment 556 participants
Start Date 2025-06-04
Primary Completion 2028-04 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2025-09-12